This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Pension Fund ABP Settles With Merck In Securities Class Action

HEERLEN, Netherlands and AMSTERDAM, Feb. 14, 2013 /PRNewswire/ --  The Dutch pension fund Stichting Pensioenfonds ABP ("ABP"), together with three co-lead plaintiffs, has reached a settlement with Merck and certain of its current and former officers and directors, whereby Merck will pay $215 million to resolve a five-year-old securities class action against all of the Merck defendants. This settlement is part of a $688 million total settlement that Merck agreed to with plaintiffs in two class actions that were combined for trial: Merck & Co., Inc. Vytorin/Zetia Securities Litigation; and Schering-Plough Corporation/Enhance Securities Litigation.

The Merck Vytorin class action, filed in 2008, is pending before Judge Dennis M. Cavanaugh in U.S. District Court for the District of New Jersey.  The settlement comes three weeks before a scheduled trial date of March 4. ABP, International Fund Management SA (part of the Deka Bank Group), the Jacksonville Police and Fire Retirement System, and the General Retirement System of the City of Detroit are the four institutional investor lead plaintiffs in the class action.  The Merck Vytorin class action settlement covers all investors who purchased Merck stock or options between December 6, 2006 and March 28, 2008.

ABP's settlement stems from claims that Merck delayed disclosing for two years results of a clinical trial called ENHANCE - which indicated that Merck's anti-cholesterol drug Vytorin had no statistical advantage in treating atherosclerosis when compared to a generic statin drug, simvastatin. Merck investors alleged that the delay caused a substantial drop in the value of their shares when results of the study were published in 2008.

Merck has denied and continues to deny these claims, contending that the company and its officers acted responsibly in connection with the ENHANCE study. The settlement is subject to approval by Judge Cavanaugh.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs